Table 2.
Clinical Characteristics and Outcome Data
|
Total Sample (N=31) |
Depressed Sample (HADS-Dep >=8) (N=17) |
|||
|---|---|---|---|---|
| Age | 50 (27–68) | 46 (32–68) | ||
| Gender | ||||
| Female | 27 (87%) | 14 (82%) | ||
| Race | ||||
| White | 27 (87%) | 15 (88%) | ||
| Af.Am. | 3 (10%) | 2 (12%) | ||
| Asian | 1 (3%) | 0 | ||
| Ethnicity | ||||
| Hispanic | 3 (10%) | 3 (18%) | ||
| Education | N(%) | N(%) | ||
| Professional Degree | 2 (6%) | 0 | ||
| Masters | 10 (32%) | 6 (35%) | ||
| 4yr | 13 (42%) | 6 (35%) | ||
| Some College | 4 (13%) | 3 (18%) | ||
| 2yr | 1 (3%) | 1 (6%) | ||
| Some HS | 1 (3%) | 1(6%) | ||
| Cancer Type | ||||
| Breast | 14 (45%) | 8 (47%) | ||
| Lymphoma | 8 (26%) | 4 (24%) | ||
| Gynecologic | 3 (10%) | 1 (6%) | ||
| Lung | 2 (6%) | 1 (6%) | ||
| Colon | 2 (6%) | 1 (6%) | ||
| Sarcoma | 1 (3%) | 1 (6%) | ||
| Thyroid | 1 (3%) | 1 (6%) | ||
| Stage | ||||
| I | 8 (26%) | 5 (29%) | ||
| II | 11(35%) | 5 (29%) | ||
| III | 6 (19%) | 3 (18%) | ||
| IV | 3 (10%) | 2 (12%) | ||
| none | 3 (10%) | 2 (12%) | ||
| Main Outcomes (Intention to Treat)* | ||||
| Total Sample |
Sample with HADS-D>=8 |
|||
| Onward (N=15) | III-Only (N=16) | Onward (N=10) | III-Only (n=7) | |
| HADS - Dep | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
| Baseline | 7.73 (4.06) | 6.63 (4.24) | 10.10 (2.02) | 10.43 (2.51) |
| Post-Tx | 5.40 (2.67) | 5.14 (3.28) | 6.50 (2.51) | 7.67 (2.16) |
| effect size | 0.72 | 0.38 | 1.27 | 0.89 |
| Adherence | ||||
| Mean logins | 20.8 (17.7) | 12.5 (12.5) | 21.5 (18.7) | 11.3 (8.6) |
| Drop-outs | 2 (13.3%) | 5 (31.3%) | 1 (10%) | 3 (42.9%) |